VANCOUVER, BRITISH COLUMBIA--(Marketwire - Aug. 28, 2012) - biOasis Technologies Inc. (TSX VENTURE:BTI) announces its board of directors elected by the shareholders at its Annual General Meeting held today:
| Robin Hutchison |
| David Clark, CA |
| Dr. Terry Pearson |
| Dr. Chris Fibiger |
| Michael Hutchison Q.C. |
| Ron Erickson |
| Greg Gubitz |
The Board also appointed the following officers of the Company:
| Robin Hutchison, President and CEO |
| David Clark, Chief Financial Officer and Corporate Secretary |
The Company also announces that is has granted as of close of business today 328,000 incentive stock options to officers and directors of the Company exercisable at $1.28 per share expiring on August 28, 2017. The options shall vest according to company's stock option plan.
ABOUT BIOASIS:
biOasis Technologies Inc. is a biopharmaceutical company engaged in the development and commercialization of products for the diagnosis and treatment of neurological diseases and disorders. Its products and technologies are intended for use within the healthcare and life science research markets. The Company is currently developing Cognitest™, a blood test for the diagnosis of Alzheimer's disease. biOasis is also developing Transcend, a proprietary molecular carrier intended to transport drugs across the Blood-Brain Barrier for treatment of a wide range of neurological, oncological and infectious disease applications.
On Behalf of the Board of Directors
Rob Hutchison, Chairman & CEO
"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."
Contact Information:
Rob Hutchison
Chairman & CEO
(778) 383.3280
rob@bioasis.ca
www.bioasis.ca